PRPO, US74019L6020

Precipio stock: Q3 revenue reaches USD 7.3 million

Published on 11/17/2026 at 03:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Product revenue rose 40 percent year over year in the quarter. Management targets a combined annualized revenue run rate above USD 40 million by end-2027.

Precipio outlines growth path

  • Product sales crossed a quarterly milestone while pathology remained the larger business.
  • Management plans to accelerate commercialization through expanded distribution and sales activities.
  • Positive adjusted EBITDA and operating cash flow supported the company during the quarter.
PRPO, US74019L6020, Illustration mit AI erstellt.

Precipio reported third-quarter 2026 revenue of USD 7.3 million on November 10, 2026, for the quarter ended September 30. In its GlobeNewswire release, the company said revenue increased 8 percent from the year-earlier quarter and from USD 7.0 million in the second quarter.

Product revenue reached USD 1.0 million, up 40 percent year over year, while pathology revenue was USD 6.3 million, 5 percent above the prior-year quarter. Adjusted EBITDA was USD 0.4 million, compared with USD 0.5 million a year earlier, and operating cash flow was USD 0.6 million.

Growth targets move into focus

Management said it aims to build product revenue to an annualized run rate above USD 10 million by the end of 2027, compared with approximately USD 4 million based on third-quarter results. It also targets an annualized pathology revenue run rate of approximately USD 30 million, implying a combined target above USD 40 million when 2027 ends.

The company said those figures are annualized exit-rate targets rather than forecasts for recognized full-year revenue. Distribution relationships with Thermo Fisher, Medline, McKesson and Cardinal Health are intended to support product commercialization, while management plans to expand its sales force in 2027.

Diagnostics platform supports expansion

Precipio is a healthcare biotechnology company based in New Haven, Connecticut, and focuses on cancer diagnostics. It provides diagnostic testing, products, reagents and laboratory services for blood cancers, including pathology services, HemeScreen genetic panels, IV-Cell culture media and ICE-COLD PCR technology.

The company develops and validates technologies in its own laboratory before commercializing products for the global laboratory community. Its pathology operation also provides a clinical platform for product development and generated the majority of operating cash flow described in the quarterly update.

Precipio company facts

  • Company: Precipio, Inc.
  • ISIN: US74019L6020
  • Ticker: PRPO
  • Home exchange: Nasdaq
  • Sector: Healthcare
  • Industry: Medical Diagnostics and Research
  • Quarter: Three months ended September 30, 2026
  • Revenue: USD 7.3 million
  • Adjusted EBITDA: USD 0.4 million
  • Operating cash flow: USD 0.6 million

US equities provide the relevant market backdrop for Precipio stock.

More news and analyses on Precipio stock are available here.

Disclaimer...
en | US74019L6020 | PRPO | boerse | 70523875 | bgmi